## References

Agu K, Oparah A. Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. Perspectives in Clinical Research. 2013;4(2):117.

Bastuji-Garin, S. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Archives of Dermatology. 1993;129(1), pp.92-96.

Beltraminelli, H., Lerch, M., Arnold, A., Bircher, A. and Haeusermann, P. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. British Journal of Dermatology. 2005;152(4), pp.780-783.

Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Medical Clinics of North America. 2010;94(4): 711–725.

Bosamiya, S. The immune reconstitution inflammatory syndrome. Indian Journal of Dermatology. 2011;56(5), p.476.

Cacoub, P., Musette, P., Descamps, V., Meyer, O., Speirs, C., Finzi, L. and Roujeau, J. The DRESS Syndrome: A Literature Review. The American Journal of Medicine. 2011;124(7), pp.588-597.

Carr, A., Vasak, E., Munro, V., Penny, R. and Cooper, D. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clinical & Experimental Immunology. 2008;97(2), pp.260-265.

Castelnuovo B, Nanyonjo A, Kamya M, Ocama P. Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia. African Health Sciences. 2008;8:133-4.

Chantachaeng W, Chularojanamontri L, Kulthanan K, Jongjarearnprasert K, Dhana N. Cutaneous adverse reactions to sulfonamide antibiotics. Asian Pacific Journal of Allergy Immunology. 2011;29:284-9.

Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. British Journal of Clinical Pharmacology. 2011;71:659-71.

Cooper RD, Wiebe N, Smith N et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clinical Infectious Diseases. 2010;51:496–505.

Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670-4

Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. Journal of Allergy Clinical Immunology. 2008;121:826-32.e5.

Fagot, J. P. et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15. 2011;1843–1848

GlaxoSmithKline. Epivir® prescribing information [package insert]. Research Triangle Park (NC): GlaxoSmithKline, 2006.

Khan DA, Solensky R. Drug allergy. Journal of Allergy Clinical Immunology. 2010;125(2 Suppl 2):S126-37

Knowles, S., & Shear, N. Recognition and Management of Severe Cutaneous Drug Reactions. Dermatologic Clinics. 2007;25(2), 245-253.

Kouotou, E., Nansseu, J., Ngono, V., Tatah, S., Zoung-Kanyi Bissek, A. and Ndjitoyap Ndam, E. Prevalence and Clinical Profile of Drug Eruptions among Anti-retroviral Therapy-Exposed HIV Infected People in Yaoundé, Cameroon. Dermatology Research and Practice. 2017;pp.1-6.

Leung JM, O'Brien JG, Wong HK et al. Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a latino male. Ann Pharmacother 2008; 42: 425–9.

Li, Y., Jin, Y., He, L., Bai, J., Liu, J., Yu, M., Chen, J., Wen, J. and Kuang, Y. Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China. Scientific Reports. 2016;6(1).

Lokhande, A., Sutaria, A., Shah, B. and Shah, A. Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011. Indian Journal of Sexually Transmitted Diseases and AIDS. 2013;34(2), p.113.

Marina, S., Semkova, K., Guleva, D., & Kazandjieva, J. Acute generalized exanthematous pustulosis (AGEP): a literature review. Scripta Scientifica Medica. 2013;45(4), 7.

Mahatme N, Narasimharao R. A study of clinical patterns and causative agents of adverse cutaneous drug reactions. Indian Journal of Drugs and Dermatology 2016;2:13-8.

Maverakis, E., Wang, E., Shinkai, K., Mahasirimongkol, S., Margolis, D., & Avigan, M. et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines. JAMA Dermatology. 2017;153(6), 587.

Mehta, U. and Maartens, G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity?. The Lancet Infectious Diseases. 2007;7(11), pp.733-738.

Ministry of Health, Republic of Indonesia. Situasi dan analisis HIV AIDS. [serial online]. 2016 [cited 2018 December 10]. Available from:http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin%20hive%20aids.pdf

Ministry of Health, Republic of Indonesia. Situasi dan analisis HIV AIDS. [serial online]. 2017 [cited 2018 December 10]. Available from:http://siha.depkes.go.id/portal/files_upload/Laporan_HIV_AIDS_TW_1_2017_rev.pdf

Mugomeri E,Olivier D,van den Heever-Kriek E.The effect of tenofovir in renal function in HIV-positive adult patients in the Roma health service area, Lesotho, southern Africa. Journal of International AIDS Society 2014;17(4 Suppl 3):19681.

Naranjo, C., Busto, U., Sellers, E., Sandor, P., Ruiz, I., Roberts, E., Janecek, E., Domecq, C. and Greenblatt, D. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981;30(2), pp.239-245.

Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. Journal of Dutch Dermatology 2015;13:625–45.

Pedoman Nasional Tatalaksana Klinis Infeksi HIV Dan Terapi Anti-retroviral Pada Orang Dewasa. Jakarta. 2012.

Pitche, P., Drobacheff-Thiebaut, C., Gavignet, B., Mercier, M. & Laurent, R. [Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients]. Annales de Dermatologie et de Venereologie. 2005;132, 970–974.

Popovic M, Shenton JM, Chen J, Baban A, Tharmanathan T, Mannargudi B, et al. Nevirapine hypersensitivity. Handbook of Experimental Pharmacology. 2010;196:437-51.

Pudukadan D, Thappa DV. Adverse cutaneous drug reactions: Clinical pattern and causative agents in a tertiary care center in South India. Indian Journal of Dermatology Venereology and Leprology. 2004;70:20-4.

Radhakrishnan, R. and Sudha, V. Highly active antiretroviral therapy induced cutaneous adverse drug reactions in patients with human immunodeficiency virus infection. International Journal of Pharmacological Science. 2010;2, pp.84-97.

Roujeau, J., Allanore, L., Liss, Y. and Mockenhaupt, M. Severe Cutaneous Adverse Reactions to Drugs (SCAR): Definitions, Diagnostic Criteria, Genetic Predisposition. Dermatologica Sinica. 2009;27: 203-209.

Rzanky B, Hamouda O, Scho¨pf E. Incidence of StevensJohnson syndrome and toxic epidermal necrolysis in patients with acquired immunodeficiency syndrome in Germany. Archives of Dermatology. 1993; 129: 1059.

Sassolas, B., Haddad, C., Mockenhaupt, M., Dunant, A., Liss, Y., Bork, K., Haustein, U., Vieluf, D., Roujeau, J. and Le Louet, H. ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis. Clinical Pharmacology & Therapeutics. 2010;88(1), pp.60-68.

Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents- a 6 yr series from Chandigarh, India. Journal of Postgraduate Medicine. 2001;47:95.

Shear NH, Knowles SR, Sullivan JR, Shapiro L. Cutaneous reactions to drugs. In: Freedberg IM, Eisen AZ, Wolff K, editors. Fitzpatrick's dermatology in general medicine. 6 th Ed. USA: McGraw Hill, Medical publishing division; 2003:1330-1336.

Shubber, Z. et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 27. 2013;1403–1412.

Sidoroff A, Haleevy S, Bainck J, et al. Acute generalized exanthematous pustulosis (AGEP): 252 Knowles & Shear a clinical reaction pattern. Journal of Cutaneous Pathology 2001;28: 113–9.

Sidoroff A. Acute generalized exanthematous pustulosis. Chemical Immunology and Allergy. 2012;97:139–148.

Tansuphaswadikul, S. et al. Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. Asian Pacific Journal of Allergy and Immunology. 2007;25, 147–154.

Tejashwani, Patel D, Bhuptani N. An observational study of cutaneous adverse drug reactions in tertiary hospital. International Journal of Research in Dermatology. 2018;4:254-8.

Temesgen Z, Beri G. HIV and drug allergy. Immunology and Allergy Clinics of North America. 2004;24:521-31.

Todd G. Adverse cutaneous drug eruptions and HIV: a clinician's global perspective. Dermatologic Clinics. 2006;24:459-72.

Vitezica, Z. G. et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22,540–541.

Yuan, J., Guo, S., Hall, D., Cammett, A., Jayadev, S., Distel, M., Storfer, S., Huang, Z., Mootsikapun, P., Ruxrungtham, K., Podzamczer, D. and Haas, D. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS. 2011;25(10), pp.1271-1280.